title: [Study on flomoxef in the perinatal period].
abstract: The placental passage and the the therapeutic efficacy of flomoxef (FMOX, 6315-S) were studied in patients in the perinatal period. A summary of the obtained results is as follows: 1. Concentrations of FMOX in maternal serum, umbilical cord serum and amniotic fluid obtained upon one-shot intravenous injections to 12 patients were compared with those obtained upon 1 hour drip infusions to 9 patients. It was found that the former means of administration gave higher concentrations that the latter. 2. Concentrations of FMOX in maternal serum, umbilical cord serum and amniotic fluid at 1 to 6 hours after administration through either method were all higher than MIC80's of recognized bacteria. 3. Clinical efficacies were evaluated in 10 patients with puerperal intrauterine infection, 7 patients with endometritis, 2 patients with pyelonephritis and 1 patient each with endo-cervicitis, amniotic fluid infection, mastitis and perineal wound infection. Clinical efficacies were excellent in 5 patients (21.7%), good in 17 patients (73.9%) and poor in 1 patient (4.4%), thus the overall efficacy rate was 95.7%. 4. Eradication of causative bacteria were obtained in all 8 cases tested, hence the eradication rate was 100%. 5. Mild diarrhea in 1 patient was the only side effect observed. No abnormal clinical laboratory test results were found in any patients.
authors.affiliation: Department of Obstetrics and Gynecology, Asahikawa Medical College.
authors.forename: K
authors.initials: K
authors.lastname: Tamate
authors.forename: K
authors.initials: K
authors.lastname: Sengoku
authors.forename: M
authors.initials: M
authors.lastname: Ishikawa
authors.forename: T
authors.initials: T
authors.lastname: Shimizu
authors.forename: H
authors.initials: H
authors.lastname: Haga
authors.forename: T
authors.initials: T
authors.lastname: Hasegawa
authors.forename: H
authors.initials: H
authors.lastname: Takada
authors.forename: K
authors.initials: K
authors.lastname: Mure
authors.forename: M
authors.initials: M
authors.lastname: Kawamura
authors.forename: Y
authors.initials: Y
authors.lastname: Torii
mesh_terms: D000328:Adult; D001419:Bacteria / Q000302:isolation & purification; D002511:Cephalosporins / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004341:Drug Evaluation; D004716:Endometritis / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy* / Q000382:microbiology; D011645:Puerperal Infection / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D002511:Cephalosporins; C045693:flomoxef